<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00943917</url>
  </required_header>
  <id_info>
    <org_study_id>ITCA 650-CLP-02</org_study_id>
    <nct_id>NCT00943917</nct_id>
  </id_info>
  <brief_title>Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety, efficacy and tolerability of various doses
      of ITCA 650 in subjects with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in HbA1c (Per Protocol)</measure>
    <time_frame>Day 0 and Week 12</time_frame>
    <description>Mean change in HbA1c over first 12 weeks (Stage I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in HbA1c (ITT)</measure>
    <time_frame>Day 0 to Week 12</time_frame>
    <description>Mean change in HbA1c through Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in HbA1c (Per Protocol)</measure>
    <time_frame>Day 0 to Week 24</time_frame>
    <description>Mean change in HbA1c through Week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in HbA1c (ITT)</measure>
    <time_frame>Day 0 to Week 24</time_frame>
    <description>Mean change in HbA1c through Week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in HbA1c (Per Protocol)</measure>
    <time_frame>Day 0 to Week 48</time_frame>
    <description>Mean change in HbA1c through Week 48</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in HbA1c (ITT)</measure>
    <time_frame>Day 0 to Week 48</time_frame>
    <description>Mean change in HbA1c through Week 48</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ITCA 650 20 mcg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ITCA 650 40 mcg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ITCA 650 20/20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ITCA 650 20/60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ITCA 650 40/40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ITCA 650 40/80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex Inj/ITCA 650 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex Inj/ITCA 650 60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ITCA 650</intervention_name>
    <description>ITCA 650 (continuous delivery of exenatide in DUROS)</description>
    <arm_group_label>ITCA 650 20 mcg/day</arm_group_label>
    <arm_group_label>ITCA 650 40 mcg/day</arm_group_label>
    <arm_group_label>ITCA 650 20/20</arm_group_label>
    <arm_group_label>ITCA 650 20/60</arm_group_label>
    <arm_group_label>ITCA 650 40/40</arm_group_label>
    <arm_group_label>ITCA 650 40/80</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide Injection</intervention_name>
    <description>twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks</description>
    <arm_group_label>Exenatide Injection</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ex Inj/ITCA 650</intervention_name>
    <description>twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650</description>
    <arm_group_label>Ex Inj/ITCA 650 40</arm_group_label>
    <arm_group_label>Ex Inj/ITCA 650 60</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females age 18-70 years

          -  Type 2 diabetes mellitus for ≥ 6 months prior to Screening Visit 1

          -  On a stable (&gt; 3 months prior to Screening Visit 1) treatment regimen of metformin
             monotherapy;

          -  Fasting plasma glucose &lt; 240 mg/dL at Screening Visit 1

          -  HbA1c ≥ 7% and ≤ 10% at Screening Visit 1

        Exclusion Criteria:

          -  Prior treatment with exenatide

          -  Treatment with any of the following antidiabetic agents within 3 months prior to
             Screening Visit 1: TZDs, sulfonylureas, DPP IV inhibitors, acarbose, or insulin
             (injected or inhaled)

          -  History of type 1 diabetes and/or history of diabetic ketoacidosis

          -  Body mass index ≥ 40 kg/m2;

          -  History of organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <zip>91710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <results_first_submitted>February 24, 2012</results_first_submitted>
  <results_first_submitted_qc>May 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2012</results_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At Stage II subjects divided into 6 total arms: ITCA 650 20 mcg/day assigned to either ITCA 650 20 mcg/day or ITCA 650 40 mcg/day; ITCA 650 40 mcg/day assigned to ITCA 650 40 mcg/day or ITCA 650 80 mcg/day; Ex Inj assigned to either ITCA 650 40 mcg/day or ITCA 650 60 mcg/day</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ITCA 650 20 mcg/Day- STAGE I</title>
          <description>ITCA 650 20 mcg/day continuous exenatide</description>
        </group>
        <group group_id="P2">
          <title>ITCA 650 40 mcg/Day- STAGE I</title>
          <description>ITCA 650 40 mcg/day continuous exenatide</description>
        </group>
        <group group_id="P3">
          <title>Exenatide Injection- STAGE I</title>
          <description>exenatide injection twice a day: 5 mcg/dose first 4 weeks then 10 mcg/dose for next 8 weeks</description>
        </group>
        <group group_id="P4">
          <title>ITCA 650 20/20- STAGE II</title>
          <description>ITCA 650 20 mcg/day first 12 weeks, then ITCA 650 20 mcg/day through Week 24</description>
        </group>
        <group group_id="P5">
          <title>ITCA 650 20/60- STAGE II</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 60 mcg/day through Week 24</description>
        </group>
        <group group_id="P6">
          <title>ITCA 650 40/40 - STAGE II</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 24</description>
        </group>
        <group group_id="P7">
          <title>ITCA 650 40/80 - STAGE II</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day through Week 24</description>
        </group>
        <group group_id="P8">
          <title>Ex Inj/ITCA 650 40 mcg/Day- STAGE II</title>
          <description>Exenatide injection twice/day for 12 weeks then ITCA 650 40 mcg/day through Week 24</description>
        </group>
        <group group_id="P9">
          <title>Ex Inj/ITCA 650 60 mcg/Day- STAGE II</title>
          <description>Exenatide injection twice/day for 12 weeks then ITCA 650 60 mcg/day through Week 24</description>
        </group>
        <group group_id="P10">
          <title>ITCA 650 20/20 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 through Week 48</description>
        </group>
        <group group_id="P11">
          <title>ITCA 650 20/40 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="P12">
          <title>ITCA 650 40/40 Contination</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="P13">
          <title>ITCA 650 40/80 Continuation</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day through Week 48</description>
        </group>
        <group group_id="P14">
          <title>Ex Inj/ITCA 650 40 Continuation</title>
          <description>Exenatide injection twice/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="P15">
          <title>Ex Inj/ITCA 650 60 Continuation</title>
          <description>Exenatide injection twice daily first 12 weeks then ITCA 650 60 mcg/day through Week 48</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>hyperglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>A1C elevation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="23"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="21"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="20"/>
                <participants group_id="P7" count="20"/>
                <participants group_id="P8" count="23"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Stage II Continuation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="15"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="13"/>
                <participants group_id="P13" count="16"/>
                <participants group_id="P14" count="15"/>
                <participants group_id="P15" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="14"/>
                <participants group_id="P11" count="15"/>
                <participants group_id="P12" count="11"/>
                <participants group_id="P13" count="13"/>
                <participants group_id="P14" count="12"/>
                <participants group_id="P15" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="2"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>hypoglycemia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>A1C elevation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ITCA 650 20 mcg/Day- STAGE I</title>
          <description>ITCA 650 20 mcg/day continuous exenatide</description>
        </group>
        <group group_id="B2">
          <title>ITCA 650 40 mcg/Day- STAGE I</title>
          <description>ITCA 650 40 mcg/day continuous exenatide</description>
        </group>
        <group group_id="B3">
          <title>Exenatide Injection- STAGE I</title>
          <description>exenatide injection twice a day: 5 mcg/dose first 4 weeks then 10 mcg/dose for next 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>ITCA 650 20/20- STAGE II</title>
          <description>ITCA 650 20 mcg/day first 12 weeks, then ITCA 650 20 mcg/day through Week 24</description>
        </group>
        <group group_id="B5">
          <title>ITCA 650 20/60- STAGE II</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 60 mcg/day through Week 24</description>
        </group>
        <group group_id="B6">
          <title>ITCA 650 40/40 - STAGE II</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 24</description>
        </group>
        <group group_id="B7">
          <title>ITCA 650 40/80 - STAGE II</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day through Week 24</description>
        </group>
        <group group_id="B8">
          <title>Ex Inj/ITCA 650 40 mcg/Day- STAGE II</title>
          <description>Exenatide injection twice/day for 12 weeks then ITCA 650 40 mcg/day through Week 24</description>
        </group>
        <group group_id="B9">
          <title>Ex Inj/ITCA 650 60 mcg/Day- STAGE II</title>
          <description>Exenatide injection twice/day for 12 weeks then ITCA 650 60 mcg/day through Week 24</description>
        </group>
        <group group_id="B10">
          <title>ITCA 650 20/20 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 through Week 48</description>
        </group>
        <group group_id="B11">
          <title>ITCA 650 20/40 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="B12">
          <title>ITCA 650 40/40 Contination</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="B13">
          <title>ITCA 650 40/80 Continuation</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day through Week 48</description>
        </group>
        <group group_id="B14">
          <title>Ex Inj/ITCA 650 40 Continuation</title>
          <description>Exenatide injection twice/day first 12 weeks then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="B15">
          <title>Ex Inj/ITCA 650 60 Continuation</title>
          <description>Exenatide injection twice daily first 12 weeks then ITCA 650 60 mcg/day through Week 48</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="0"/>
            <count group_id="B6" value="0"/>
            <count group_id="B7" value="0"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="0"/>
            <count group_id="B10" value="0"/>
            <count group_id="B11" value="0"/>
            <count group_id="B12" value="0"/>
            <count group_id="B13" value="0"/>
            <count group_id="B14" value="0"/>
            <count group_id="B15" value="0"/>
            <count group_id="B16" value="155"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="8.3"/>
                    <measurement group_id="B2" value="53.3" spread="8.9"/>
                    <measurement group_id="B3" value="53.8" spread="9.6"/>
                    <measurement group_id="B16" value="53.7" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B16" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B16" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B16" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B16" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B16" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B16" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (Per Protocol)</title>
        <description>Mean change in HbA1c over first 12 weeks (Stage I)</description>
        <time_frame>Day 0 and Week 12</time_frame>
        <population>Per protocol analysis- Only subjects with values at baseline and Week 12 endpoint are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20 mcg/Day - STAGE I</title>
            <description>ITCA 650 20 mcg/day through Week 12</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 40 mcg/Day - STAGE I</title>
            <description>ITCA 650 40 mcg/day through Week 12</description>
          </group>
          <group group_id="O3">
            <title>Exenatide Injection - STAGE I</title>
            <description>Exenatide injection twice daily: 5 mcg/dose first 4 weeks then 10 mcg/dose through Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (Per Protocol)</title>
          <description>Mean change in HbA1c over first 12 weeks (Stage I)</description>
          <population>Per protocol analysis- Only subjects with values at baseline and Week 12 endpoint are included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.905"/>
                    <measurement group_id="O2" value="-1.04" spread="0.713"/>
                    <measurement group_id="O3" value="-0.82" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (ITT)</title>
        <description>Mean change in HbA1c through Week 12</description>
        <time_frame>Day 0 to Week 12</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20 mcg/Day - STAGE I</title>
            <description>ITCA 650 20 mcg/day through Week 12</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 40 mcg/Day - STAGE I</title>
            <description>ITCA 650 40 mcg/day through Week 12</description>
          </group>
          <group group_id="O3">
            <title>Exenatide Injection - STAGE I</title>
            <description>Exenatide injection twice daily: 5 mcg/dose first 4 weeks then 10 mcg/dose through Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (ITT)</title>
          <description>Mean change in HbA1c through Week 12</description>
          <population>Intent to treat analysis</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.93" spread="0.882"/>
                    <measurement group_id="O2" value="-0.96" spread="0.724"/>
                    <measurement group_id="O3" value="-0.75" spread="0.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (Per Protocol)</title>
        <description>Mean change in HbA1c through Week 24</description>
        <time_frame>Day 0 to Week 24</time_frame>
        <population>Per protocol analysis - Only subjects with values at baseline and Week 24 endpoint are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20/20</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 20/60</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O3">
            <title>ITCA 650 40/40</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O4">
            <title>ITCA 650 40/80</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O5">
            <title>Ex Inj/ITCA 650 40</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O6">
            <title>Ex Inj/ITCA 650 60</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (Per Protocol)</title>
          <description>Mean change in HbA1c through Week 24</description>
          <population>Per protocol analysis - Only subjects with values at baseline and Week 24 endpoint are included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.89" spread=".660"/>
                    <measurement group_id="O2" value="-1.26" spread=".950"/>
                    <measurement group_id="O3" value="-0.67" spread=".908"/>
                    <measurement group_id="O4" value="-1.36" spread="0.664"/>
                    <measurement group_id="O5" value="-1.01" spread="0.823"/>
                    <measurement group_id="O6" value="-1.51" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (ITT)</title>
        <description>Mean change in HbA1c through Week 24</description>
        <time_frame>Day 0 to Week 24</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20/20</title>
            <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 20 mcg/day</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 20/60</title>
            <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 60 mcg/day</description>
          </group>
          <group group_id="O3">
            <title>ITCA 650 40/40</title>
            <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day</description>
          </group>
          <group group_id="O4">
            <title>ITCA 650 40/80</title>
            <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day</description>
          </group>
          <group group_id="O5">
            <title>Ex Inj/ITCA 650 40</title>
            <description>Exenatide injection first 12 weeks then ITCA 650 40 mcg/day</description>
          </group>
          <group group_id="O6">
            <title>Ex Inj/ITCA 650 60</title>
            <description>Exenatide injection first 12 weeks then ITCA 650 60 mcg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (ITT)</title>
          <description>Mean change in HbA1c through Week 24</description>
          <population>Intent to treat analysis</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.89" spread="0.660"/>
                    <measurement group_id="O2" value="-1.26" spread="0.950"/>
                    <measurement group_id="O3" value="-0.70" spread="0.892"/>
                    <measurement group_id="O4" value="-1.36" spread="0.664"/>
                    <measurement group_id="O5" value="-1.01" spread="0.823"/>
                    <measurement group_id="O6" value="-1.51" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (Per Protocol)</title>
        <description>Mean change in HbA1c through Week 48</description>
        <time_frame>Day 0 to Week 48</time_frame>
        <population>Per protocol - Only subjects with values at baseline and Week 48 endpoint are included.</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20/20</title>
            <description>Stage II Continuation</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 20/60</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O3">
            <title>ITCA 650 40/40</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O4">
            <title>ITCA 650 40/80</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O5">
            <title>Ex Inj/ITCA 650 40</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
          <group group_id="O6">
            <title>Ex Inj/ITCA 650 60</title>
            <description>Stage II &amp; Stage II Continuation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (Per Protocol)</title>
          <description>Mean change in HbA1c through Week 48</description>
          <population>Per protocol - Only subjects with values at baseline and Week 48 endpoint are included.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.493"/>
                    <measurement group_id="O2" value="-1.23" spread="0.908"/>
                    <measurement group_id="O3" value="-0.69" spread="1.182"/>
                    <measurement group_id="O4" value="-1.37" spread="0.837"/>
                    <measurement group_id="O5" value="-1.45" spread="0.895"/>
                    <measurement group_id="O6" value="-1.88" spread="1.212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in HbA1c (ITT)</title>
        <description>Mean change in HbA1c through Week 48</description>
        <time_frame>Day 0 to Week 48</time_frame>
        <population>Intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ITCA 650 20/20</title>
            <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 20 mcg/day</description>
          </group>
          <group group_id="O2">
            <title>ITCA 650 20/60</title>
            <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 60 mcg/day</description>
          </group>
          <group group_id="O3">
            <title>ITCA 650 40/40</title>
            <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day</description>
          </group>
          <group group_id="O4">
            <title>ITCA 650 40/80</title>
            <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day</description>
          </group>
          <group group_id="O5">
            <title>Ex Inj/ITCA 650 40</title>
            <description>Exenatide injection first 12 weeks then ITCA 650 40 mcg/day</description>
          </group>
          <group group_id="O6">
            <title>Ex Inj/ITCA 650 60</title>
            <description>Exenatide injection first 12 weeks then ITCA 650 60 mcg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in HbA1c (ITT)</title>
          <description>Mean change in HbA1c through Week 48</description>
          <population>Intent to treat analysis</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.651"/>
                    <measurement group_id="O2" value="-1.25" spread="0.880"/>
                    <measurement group_id="O3" value="-0.48" spread="1.555"/>
                    <measurement group_id="O4" value="-1.40" spread="0.803"/>
                    <measurement group_id="O5" value="-1.16" spread="0.988"/>
                    <measurement group_id="O6" value="-1.84" spread="1.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ITCA 650 20 mcg/Day</title>
          <description>ITCA 650 20 mcg/day continuous exenatide</description>
        </group>
        <group group_id="E2">
          <title>ITCA 650 40 mcg/Day</title>
          <description>ITCA 650 40 mcg/day continuous exenatide</description>
        </group>
        <group group_id="E3">
          <title>Exenatide Injection</title>
          <description>exenatide injection twice daily dosing: 5 mcg/dose first 4 weeks then 10 mcg/day next 8 weeks</description>
        </group>
        <group group_id="E4">
          <title>ITCA 650 20/20</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 20 mcg/day</description>
        </group>
        <group group_id="E5">
          <title>ITCA 650 20/60</title>
          <description>ITCA 650 20 mcg/day first 12 weeks then ITCA 650 60 mcg/day</description>
        </group>
        <group group_id="E6">
          <title>ITCA 650 40/40</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 40 mcg/day</description>
        </group>
        <group group_id="E7">
          <title>ITCA 650 40/80</title>
          <description>ITCA 650 40 mcg/day first 12 weeks then ITCA 650 80 mcg/day</description>
        </group>
        <group group_id="E8">
          <title>Ex Inj/ITCA 650 40</title>
          <description>Exenatide injection first 12 weeks then ITCA 650 40 mcg/day</description>
        </group>
        <group group_id="E9">
          <title>Ex Inj/ITCA 650 60</title>
          <description>Exenatide injection first 12 weeks then ITCA 650 60 mcg/day</description>
        </group>
        <group group_id="E10">
          <title>ITCA 650 20/20 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks, then ITCA 650 20 mcg/day through Week 48</description>
        </group>
        <group group_id="E11">
          <title>ITCA 650 20/60 Continuation</title>
          <description>ITCA 650 20 mcg/day first 12 weeks, then ITCA 650 60 mcg/day through Week 48</description>
        </group>
        <group group_id="E12">
          <title>ITCA 650 40/40 Continuation</title>
          <description>ITCA 650 40 mcg/day first 12 weeks, then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="E13">
          <title>ITCA 650 40/80 Continuation</title>
          <description>ITCA 650 40 mcg/day first 12 weeks, then ITCA 650 80 mcg/day through Week 48</description>
        </group>
        <group group_id="E14">
          <title>Ex Inj/ITCA 40 Continuation</title>
          <description>Exenatide twice/day first 12 weeks, then ITCA 650 40 mcg/day through Week 48</description>
        </group>
        <group group_id="E15">
          <title>Ex Inj/ITCA 650 60 Continutation</title>
          <description>Exenatide injection first 12 weeks, then ITCA 650 60 mcg/day through Week 48</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDra 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholecyctitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>rectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion, spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDra 12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="53"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="23"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="51"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E3" events="20" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" events="9" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="6" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease (GERD)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>early satiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>incision site hematoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>incision site pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>incision site hemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>incision site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>incision site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>incision site complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right to submit multicenter results within 12 months after completion of the study. Thereafter, PI may publish the results of its data after submitting advance copy of the planned publication to sponsor. PI to agree to sponsor changes regarding deletion of confidential information, reasonable changes, or a delay of up to 90 days for patent purposes.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>8 subjects (4 in 20, 1 in 40 and 3 in ex inj)completed StI but not randomized to St II; 3 subjects (2 in 20/20 &amp; 1 in 40/80) who completed St I, randomized to St II but not given study drug. St II Cont was optional, so not all pts elected to continue</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michelle Baron MD</name_or_title>
      <organization>Intarcia Therapeutics, Inc</organization>
      <phone>510-782-7800</phone>
      <email>clinicaltrials@intarcia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

